DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rebif (Interferon Beta-1a) - Published Studies

 
 



Rebif Related Published Studies

Well-designed clinical trials related to Rebif (Interferon Beta-1A)

Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of measurements in two different laboratories. [2013]

Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial. [2012]

Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. [2012]

Interferon beta for secondary progressive multiple sclerosis. [2012]

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. [2012]

Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial. [2011.12.15]

Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation. [2011.12]

Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. [2011.08]

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. [2011.06]

Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a. [2011.06]

Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. [2011.04.18]

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. [2011.04]

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. [2010.07]

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. [2010.07]

Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis. [2010.07]

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. [2010.05.15]

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. [2010.05]

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial. [2010.04]

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. [2010.04]

The therapeutic effect of Avonex, Rebif and Betaferon on EDSS and relapse in multiple sclerosis: a comparative study. [2010.03]

Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. [2010.02.23]

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. [2010.02.04]

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS). [2010.01]

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. [2010]

Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. [2010]

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. [2010]

Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study. [2009.12]

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. [2009.08]

Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. [2009.06]

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. [2009.06]

Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. [2009.03.20]

Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response. [2009.03]

Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. [2008.09.15]

Interferon Beta 1a versus Interferon Beta 1a plus Ribavirin for the Treatment of Chronic Hepatitis C in Chinese Patients: A Randomized, Placebo-Controlled Trial. [2008.08]

Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis. [2008.06.21]

Interferon Beta 1a versus Interferon Beta 1a plus Ribavirin for the Treatment of Chronic Hepatitis C in Chinese Patients: A Randomized, Placebo-Controlled Trial. [2007.12.13]

Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. [2007.04]

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. [2006.09.26]

Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. [2006.05]

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. [2006.04.11]

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. [2006.03.02]

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. [2006.02]

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. [2005.12.15]

Response to interferon beta-1a treatment in African American multiple sclerosis patients. [2005.11]

A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. [2005.10]

Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. [2005.08.07]

The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. [2005.08]

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. [2005.07.12]

Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. [2005.06]

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. [2005.05]

Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. [2005.04]

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. [2005.02]

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. [2005.01]

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. [2004.10.23]

Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a. [2004.10.13]

Defining interferon beta response status in multiple sclerosis patients. [2004.10]

Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients. [2004.09]

Overview of London trial of intramuscular interferon-beta Ia in primary-progressive multiple sclerosis. [2004.06]

Visual evoked potentials in multiple sclerosis patients treated with interferon beta-1a. [2004.06]

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. [2004.05]

Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. [2004.04]

A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. [2004]

A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome. [2003.11.11]

[Open trial of the effectiveness of interferon beta 1a (Avonex) in the treatment of multiple sclerosis in Poland: MRI results.] [2003.11]

The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta. [2003.11]

Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. [2003.09]

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. [2003.08]

Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial. [2003.08]

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. [2003.06]

Interferon beta-1a in primary progressive multiple sclerosis. [2003.02.15]

Interferon beta 1a for secondary progressive multiple sclerosis. [2003.02.15]

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. [2003.01.14]

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. [2003.01.14]

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. [2003]

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. [2002.11.26]

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. [2002.11.26]

Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. [2002.09.10]

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. [2002.09.10]

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). [2002.04.27]

A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). [2002.04.01]

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. [2002.04]

Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy. [2002.02]

Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: a categorical disability trend analysis. [2002.02]

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. [2001.11.27]

Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. [2001.10]

T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. [2001.07]

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. [2001.06.12]

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. [2000.09.28]

Extended observations on MS patients treated with IM interferon-beta1a (Avonex): implications for modern MS trials and therapeutics. [2000.07.24]

The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. [2000.06]

Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group. [2000.01.11]

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. [1999.12]

Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. [1999.10]

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. [1999.09.01]

[Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis] [1999.08]

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. [1999.08]

Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. [1999.07.13]

Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. [1999.06.10]

Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a. [1999.06]

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. [1999.04.12]

Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B. [1999.01.15]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014